CARTIVA®

A unique biomedical polymer that mimics natural cartilage and aids in smooth joint articulation and mobility.3

Unlike LRTI and Trapeziectomy, Cartiva® maintains the normal anatomy by sparing the trapezium and preserving joint height.

Cartiva SCI does not "burn a bridge" to excellent pain relief and successful functional outcomes, if a revision procedure is needed.2

-67%

Reduction in Pain1

VAS Pain Score

Cartiva pain reduction data

A substantial and clinically meaningful reduction in pain using the Visual Analog Scale (VAS) was observed for Cartiva patients at 12 months. 80% of Cartiva implant patients demonstrated a clinically meaningful reduction in pain from baseline at 12 months.1,4

-46%

QuickDASH Score1

Cartiva patients demonstrate improvement in QuickDASH score.

Cartiva QuickDash improvement data for hand

Functional activities were evaluated using the QuickDash. A substantial reduction (improvement) was observed in the mean QuickDash scores at 12 months. 94% of Cartiva implant patients demonstrated a clinically meaningful reduction in disability (improvement in function) from baseline at 12 months.1,5

Clinical Trials

  • A Prospective Study to Evaluate the Safety and Effectiveness of the Cartiva® Synthetic Cartilage Implant for CMC in the Treatment of First Carpometacarpal Joint Osteoarthritis
    View full study
  • Safety and Effectiveness of Cartiva Implant in the Treatment of First CMC Joint Osteoarthritis Compared to LRTI (GRIP 2)
    View full study

 

Clinical Trials

Download PDF Brochure

Cartiva® CMC Joint Surgical Procedure

CONTACT US

Interested in offering Cartiva® to patients?

Fill out the form below for more details.

I'd like more information about Cartiva®
I'd like to schedule a demonstration

Footnotes

1 Data on file at Cartiva; n = 49 @ 12 months, GRIP Study.

2 Bainbridge L.C., et al. “A prospective, multicenter clinical trial to assess safety and efficacy of a synthetic cartilage implant for treatment of Eaton-Littler stage II/III first CMC joint osteoarthritis: Cartiva GRIP Trial.” BSSH Abstract. 2017 July 14; Abstract Ref 31911.

3 Oka M, Ushio K, Kumar P, Ikeuchi K, Hyon SH, Nakamura T, Fujita H. Development of artificial articular cartilage. Proc Inst Mech Eng H. 2000;214(1):59-68.

4 Dworkin RH, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008 Feb;9(2):105-21. Epub 2007 Dec 11.

5 Franchignoni, Franco, et al. “Minimal clinically important difference of the disabilities of the arm, shoulder and hand outcome measure (DASH) and its shortened version (QuickDASH).” journal of orthopaedic & sports physical therapy 44.1 (2014): 30-39.

Cartiva’s Synthetic Cartilage Implant is not approved for use in the 1st CMC joint in the United States. Currently only available for use in Europe and Canada.

© 2008-2018. All Rights Reserved
Company Reg. No: 6545496